The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical condition characterized by large pathophysiology heterogeneity with lack of effective therapies as proven by the disappointing results generated by randomized controlled trials. The innovative therapeutic concept provided by s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gronda, Edoardo, Vanoli, Emilio, Iacoviello, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944492/
https://www.ncbi.nlm.nih.gov/pubmed/33727901
http://dx.doi.org/10.1093/eurheartj/suaa140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944492/
https://www.ncbi.nlm.nih.gov/pubmed/33727901
http://dx.doi.org/10.1093/eurheartj/suaa140

Ejemplares similares